Care Access, the decentralized research organization (DRO), announced its expanded partnership with Eli Lilly and Company (Lilly) to broaden patient access to clinical trials and increase representation of minority group members, including African American, Hispanic, and LatinX populations.
Lilly has tapped Care Access in its Phase III breast cancer clinical trial, eMonarcHER, designed to evaluate the safety and efficacy of Abemaciclib (LY2835219) in participants with hormone receptor positive and human epidermal receptor II positive, high risk, early breast cancer who are taking hormone therapy after surgery.
This study aims to engage diverse groups of physicians and patients to conduct research that is more fully representative of the U.S. population. To increase enrollment, Care Access will utilize its Patient Access team to establish and foster local community partners including health care systems, physician groups, diversity-focused groups, advocacy groups, and community centers that serve underrepresented minority populations.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.